CRAD B Stock Overview
Develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the America, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
C-Rad AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 29.75 |
| 52 Week High | SEK 49.95 |
| 52 Week Low | SEK 27.00 |
| Beta | 1.01 |
| 1 Month Change | 5.31% |
| 3 Month Change | -20.45% |
| 1 Year Change | -29.00% |
| 3 Year Change | -43.55% |
| 5 Year Change | -34.33% |
| Change since IPO | 98.33% |
Recent News & Updates
Recent updates
Sentiment Still Eluding C-Rad AB (publ) (STO:CRAD B)
Oct 24
Market Participants Recognise C-Rad AB (publ)'s (STO:CRAD B) Earnings Pushing Shares 29% Higher
Jun 02Returns On Capital Are A Standout For C-Rad (STO:CRAD B)
Mar 01C-Rad's (STO:CRAD B) Earnings Are Weaker Than They Seem
Feb 15Do C-Rad's (STO:CRAD B) Earnings Warrant Your Attention?
Feb 03C-Rad AB (publ)'s (STO:CRAD B) Popularity With Investors Is Clear
Jan 19Is Now The Time To Look At Buying C-Rad AB (publ) (STO:CRAD B)?
Oct 28Returns Are Gaining Momentum At C-Rad (STO:CRAD B)
Aug 16Are Investors Undervaluing C-Rad AB (publ) (STO:CRAD B) By 45%?
Dec 14Is Now An Opportune Moment To Examine C-Rad AB (publ) (STO:CRAD B)?
Jul 20Returns Are Gaining Momentum At C-Rad (STO:CRAD B)
May 07Earnings Miss: C-Rad AB (publ) Missed EPS By 5.5% And Analysts Are Revising Their Forecasts
Jan 30C-Rad (STO:CRAD B) Shareholders Will Want The ROCE Trajectory To Continue
Jul 03Will the Promising Trends At C-Rad (STO:CRAD B) Continue?
Mar 05Are C-Rad's (STO:CRAD B) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 07
What Percentage Of C-Rad AB (publ) (STO:CRAD B) Shares Do Insiders Own?
Jan 17Shareholder Returns
| CRAD B | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -3.6% | 0.4% | -2.7% |
| 1Y | -29.0% | -8.1% | 4.6% |
Return vs Industry: CRAD B underperformed the Swedish Medical Equipment industry which returned -8.1% over the past year.
Return vs Market: CRAD B underperformed the Swedish Market which returned 4.6% over the past year.
Price Volatility
| CRAD B volatility | |
|---|---|
| CRAD B Average Weekly Movement | 5.8% |
| Medical Equipment Industry Average Movement | 7.0% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.4% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: CRAD B has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: CRAD B's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 98 | Cecilia de Leeuw | www.c-rad.com |
C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the America, and the Asia Pacific. Its products include Sentinel 4DCT, a laser-based optical surface scanning system; Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solution for patient set up and intra-fraction breath hold reproducibility; Catalyst+ PT, a surface image guided radiation therapy, that supports proton therapy from simulation and treatment; and Catalyst+ HD Ring Gantry solution for patient positioning, real-time motion monitoring, and respiratory gating. The company provides Catalyst, a 4D surface guided radiation therapy (SGRT) solution; Catalyst HD, a SGRT solution on stereotactic radiation therapy for online patient tracking before and during treatment delivery; Catalyst PT, a tracking solution for particle therapy; and visual coaching solutions used for prospective and retrospective radiotherapy.
C-Rad AB (publ) Fundamentals Summary
| CRAD B fundamental statistics | |
|---|---|
| Market cap | SEK 998.96m |
| Earnings (TTM) | SEK 57.93m |
| Revenue (TTM) | SEK 485.92m |
17.2x
P/E Ratio2.1x
P/S RatioIs CRAD B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRAD B income statement (TTM) | |
|---|---|
| Revenue | SEK 485.92m |
| Cost of Revenue | SEK 152.19m |
| Gross Profit | SEK 333.73m |
| Other Expenses | SEK 275.80m |
| Earnings | SEK 57.93m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 07, 2025
| Earnings per share (EPS) | 1.73 |
| Gross Margin | 68.68% |
| Net Profit Margin | 11.92% |
| Debt/Equity Ratio | 0% |
How did CRAD B perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 01:02 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
C-Rad AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Victor Forssell | ABG Sundal Collier Sponsored |
| Christian Lee | Pareto Securities |